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Background: Empyema thoracis remains a major problem in developing countries. Clinical
outcomes in tuberculous empyema are generally believed to be worse than in non-
tuberculous aetiologies because of the presence of concomitant fibrocavitary parenchymal
disease, frequent bronchopleural fistulae and poor general condition of patients. We
performed a prospective study over a 2-year period with the objective of comparing the
clinical characteristics and outcomes of patients with tuberculous vs. non-tuberculous
empyema.
Methods: Prospective study of all cases of non-surgical thoracic empyema seen at a
tertiary care centre in North India over a 2-year period. A comparative analysis of clinical
characteristics, treatment modalities and outcomes of patients with tuberculous vs. non-
tuberculous empyema was carried out. Factors associated with poor outcomes were
analysed using multivariate logistic regression.
Results: One hundred and seventeen cases of empyema were seen in the study period of
which 95 had non-tuberculous and 41 had tuberculous empyema. Malnutrition and
bronchopleural fistulae (BPF) were more common and duration of symptoms longer in the
tuberculous empyema group. Time to resolution of fever, duration of pleural drainage and
pleural thickening 42 cm were significantly greater as well. Eight (10.5%) patients with
non-tuberculous empyema and four (9.8%) with tuberculous empyema succumbed.
Presence of a BPF was significantly associated with poor outcomes on multivariate logistic
regression analysis.Elsevier Ltd. All rights reserved.
6043765; fax: +91 172 2745959.
yahoo.co.in (P. Malhotra), skjindal@indiachest.org (S.K. Jindal).
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India though it ranked second amongst all causes of empyema after community acquired
lung infections in this study. Tuberculous empyema is associated with longer duration of
symptoms, greater duration of pleural drainage and more residual pleural fibrosis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Thoracic empyema remains a common problem both in the
developed as well as developing world. In the former
pulmonary infections and thoracic trauma are the usual
causes while pulmonary infections including tuberculosis
account for the majority of cases in the latter. Despite the
availability of potent anti-tubercular drugs and improved
surgical techniques tuberculous empyema remains a major
problem in developing countries responsible for consider-
able morbidity and mortality. Clinical outcomes in tubercu-
lous empyema are generally believed to be worse than in
non-tuberculous aetiologies because of the presence of
concomitant fibrocavitary parenchymal disease, high bacil-
lary load, frequent development of bronchopleural fistulae
and poor general condition of patients. To the best of our
knowledge no study so far has directly compared clinical
features and outcomes of patients with tuberculous empye-
ma with those of non-tuberculous causes of empyema. We
performed a prospective study over a 2-year period with the
objective of comparing the clinical characteristics and




This study was a prospective analysis of all cases of non-
surgical thoracic empyema seen by/admitted under the
Department of Pulmonary and Critical Care Medicine of the
Postgraduate Institute of Medical Education and Research
(PGIMER), Chandigarh, India over a 2-year period between
January 2003 and December 2004.
Patient selection
Inclusion criteria. Patients aged more than 12 years with
clinical evidence of infection as assessed by the treating
physician on the basis of clinical indicators such as fever, an
elevated white-cell count, and an elevated serum level of
C-reactive protein, and pleural effusions that fulfilled at
least one of the following criteria were included in this
study: (i) frank pus or purulent appearing fluid on diagnostic
pleural aspiration, (ii) positive pleural fluid culture, and (iii)
positive pleural fluid gram stain. Empyema arising secondary
to the performance of the following procedures were also
included: diagnostic or therapeutic thoracentesis, pleural
biopsy and tube thoracostomy for spontaneous pneumothor-
ax or malignant pleural effusion. Written informed consent
was taken from all patients and the study was cleared by the
Institute’s ethics committee.Exclusion criteria.(i) empyema secondary to penetrating or blunt trauma
chest,(ii) empyema secondary to any surgical procedure, e.g.
esophagectomy, pneumonectomy, etc.Study procedure
Detailed demographic and clinical parameters were evaluated
in all patients fulfilling the inclusion criteria: age and sex,
symptoms and their duration (fever, cough, expectoration,
haemoptysis, chest pain, dyspnoea, and loss of appetite and
weight). The presence of any comorbid illness was documen-
ted including chronic lung disease, diabetes mellitus, HIV
infection, rheumatoid arthritis, chronic renal failure, chronic
liver disease and malignancy. Chest radiographs were obtained
in all patients while ultrasound (USG) and computed
tomography (CT) were carried out when deemed necessary
by the treating physician. Pleural fluid was collected under
strict asepsis by thoracentesis and total leukocyte count
(TLC), differential leukocyte count (DLC); protein, sugar;
gram stain and culture sensitivity were performed in all
patients unless pleural fluid was grossly purulent in which case
only the latter investigation was sent. Mycobacterial smear
and culture was sent in patients with suspected tuberculous
empyema. Complete blood counts, renal and liver function
tests and blood culture were sent in all patients. Other
clinically relevant investigations (e.g., arterial blood gas
analysis, HIV serology, ultrasound and/or CT abdomen,
amoebic serology) were also performed if indicated.
Aetiology of empyema was decided based on the history,
physical examination, radiology, empyema fluid analysis as
well as other clinically relevant investigations. A diagnosis of
tuberculous empyema was defined as definite if pleural fluid
smear and/or culture was positive for acid-fact bacilli
(AFB)/Mycobacterium tuberculosis on two or more occa-
sions. Probable tuberculous empyema was defined as
empyema in patients in who had radiological evidence of
active pulmonary tuberculosis on CT scans (nodular con-
solidation in apical segments/tree-in-bud appearance/med-
iastinal lymphadenopathy with central necrosis) or
concomitant positive sputum smears for AFB. Patients who
had radiological features suggestive of past/inactive TB
(apical fibro-calcific lesions, parenchymal bands or thin-
walled cavities alone without surrounding areas of con-
solidation or tree-in-bud appearance) were not deemed to
have tuberculous empyema. Bronchopleural fistula (BPF)
was diagnosed if the CXR prior to tube thoracostomy
revealed pyopneumothorax and air leak through the tube
thoracostomy persisted for more than 24 h after tube
insertion.
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or, if fluid was either loculated or difficult to approach by
conventional tube thoracostomy, by the placement of a
pigtail catheter under ultrasound guidance. All patients
received antibiotic therapy, intravenous for 7–14 days
followed by an equivalent oral agent for 2–4 weeks
depending on the clinical response. The most commonly
administered agents were a combination of a third genera-
tion cephalosporin and clindamycin or a b-lactam-b-lacta-
mase inhibitor alone. Antibiotics were changed if culture
revealed a resistant organism or empirically if there was no
clinical response (defined as persistent fever and purulent
drainage) by day seven after tube thoracostomy. Intrapleur-
al streptokinase (STK) was used in selected patients with
empyema if financial constraints were not present in whom
drainage of pus by tube thoracostomy or pigtail catheter had
declined to less than 50ml of pus on two consecutive days
and there was evidence of persistent sepsis and undrained
pleural fluid on ultrasound of the chest.
The following parameters were monitored to assess the
progress and outcomes of patients: time to fever resolution,
duration of pleural drainage, duration of hospitalisation,
need for surgery, extent of pleural thickening (defined as the
largest linear dimension of pleural thickening in centi-
meters, more than or less that 2 cm on CXRPA at the time of
tube/catheter removal), and mortality. Poor outcomes were
defined as duration of pleural drainage greater than 14 days,
need for surgery, and/or death.
Statistical analysis
Statistical analyses were performed using the SPSS version
10.0 (SPSS inc., Chicago, IL) software for MS-Windows.
Descriptive frequencies were expressed using mean (stan-
dard deviation) and median (range). Differences between
continuous variables were compared using the Mann
Whitney U test and Friedman’s test, as applicable, and that
of categorical variables with the w2-test. Risk factors for
poor outcomes were evaluated using multivariable logistic
regression analysis. Initially the variables were analysed
using univariate analysis to derive crude odds ratio and if
found significant (Po0.1) these variables were then entered
in a multivariate logistic.
Results
Patient characteristics
One hundred and seventeen cases of empyema were
encountered during the study period. Their ages ranged
from 13 to 81 years (mean 40.9, SD 16.2). Most cases
(n ¼ 48%, 41%) were in the age group of 21–40 years. Co-
morbid illnesses (Table 1) were present in 59 (50.4%)
patients of which the commonest were chronic pulmonary
parenchymal disease and diabetes mellitus. Patients with
tuberculous empyema were significantly more likely to have
diabetes mellitus than those with non-tuberculous aetiolo-
gies. More than one co-morbid illness was present in 14
patients. Malnutrition and BPF were more common and
duration of symptoms longer in the tuberculous empyema
group. In addition, percentage polymorphs in pleural fluidwere lower and pleural fluid protein level was significantly
higher.
Bacteriologic spectrum
Pleural fluid gram stain was positive in 21 (18.1%) patients
while 72 bacteria were isolated in 55 patients on pleural
fluid bacterial cultures (Table 2). Thirteen patients grew two
organisms, and two grew three organisms in pleural fluid.
Acid-fast bacilli were identified in pleural fluid from 20
patients. In five of these patients, Mycobacterium tubercu-
losis was isolated on culture. In addition one patient’s
pleural fluid repeatedly grew Aspergillus fumigatus during
his hospital stay and he was administered 1.2 g of ampho-
tericin B.
Two categories of pleural space infection were identified:
(i) primary infection in which an organism was isolated from
the culture sent at initial presentation and (ii) super-
infection in which the initial culture was sterile but a culture
sent at a later date during the hospitalisation was positive.
In cases with primary infection aerobic organisms were
isolated on 41 occasions while four pleural fluid cultures
grew anaerobic bacteria. Twenty-six organisms were iso-
lated as superinfections, the majority of which were gram-
negative bacilli. Patients who developed superinfection
were younger (mean age 35 years vs. 43 years, Po0.05),
more likely to be female, malnourished (BMIo18.5 kg/m2 in
62.9% vs. 30%;o0.05), and have a tuberculous aetiology of
empyema than those who did not (51.9% vs. 30%).
Aetiology of empyema
Five broad categories of disorders were identified in the
aetiology of empyema (Table 3) of which the largest was
that of empyemas secondary to broncho-pulmonary infec-
tion (87 cases, 74.3%). Community acquired bacterial
infections (44 cases, 37.7%) including 32 (27.4%) pneumonias
and 12 (10.3%) lung abscesses were the commonest causes
overall, closely followed by tuberculosis in 41 cases (35%). A
definite diagnosis of tuberculous empyema was made in 20
patients by demonstration of acid-fast bacilli on pleural fluid
examination while the remaining cases either had radi-
ological evidence of active pulmonary tuberculosis on CT
scans (nodular consolidation in apical segments/tree-in-bud
appearance/mediastinal lymphadenopathy with central
necrosis) or positive sputum smears for AFB and were
labeled as probable tuberculous empyema. Twenty-four
patients with tuberculosis also had microbiological evidence
of co-existent bacterial infection. Interestingly, four of the
76 patients with non-tuberculous empyema had evidence of
old healed pulmonary TB on CT scans. They were deemed
not to have tuberculous empyema as AFB/M.TB could not be
demonstrated on repeated pleural fluid or sputum samples
and they responded satisfactorily to antibiotics. Twenty-
eight of the 41 patients with tuberculous empyema were
tested for HIV infection by ELISA and all were found to be
negative. Pleural fluid adenosine deaminase levels were
checked in 36 patients (those who did not have frankly
purulent pleural fluid) including 11 who were subsequently
proven to have tuberculous empyema and ranged between
12 and 164 IU/ml with a mean of 67 IU/ml (SD 42). There was
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Table 1 Comparison of clinical and demographic characteristics of patients with tuberculous vs. non-tuberculous empyema.
Clinical characteristic Non-tuberculous
empyema (n ¼ 76)
Tuberculous empyema
(n ¼ 41)
Age in years (mean (SD)) 43 (17) 38 (14)
Male sex (n (%)) 28 (68.3) 57 (75)
Co-morbid illness
Chronic lung disease (n, %) 13 (17.1) 18 (43.9)
Post-TB fibrocavitary disease 4 (5.3) 13 (31.7)
COPD 7 (9.2) 5 (12.2)
Others 2 (2.6) 0
Diabetes mellitus (n, %) 4 (5.3) 16 (39)
Malignancy (n, %) 6 (7.9) 1 (2.4)
Lung 5 (6.6) 1 (2.4)
Oesophagus 1 (1.3) 0
Alcohol-related liver disease (n, %) 3 (3.9) 2
Immunosuppression (n, %) 4 (5.2) 2 (4.9)
Drug related 3 (3.9) 2 (4.9)
HIV infection 1 (1.3) 0
Miscellaneous (n, %) 4 (5.2) 2 (4.9)
Duration of symptoms (median, days) 15 37.5
BMIo18.5 kg/m(n (%)) 22 (28.9) 23 (56.1)
SIRS (n (%)) 66 (86.8) 35 (85.4)
BPF (n (%)) 17 (22.4) 32 (78.1)
Massive effusion (n (%)) 13 (17.1) 9 (22)
Pleural fluid TLC per mm3 (median) 9600 8000
Pleural fluid percentage polymorphs (median) 90 75
Pleural fluid protein (mean (SD), g/dl) 4.3 (1.7) 5 (1.9)
Pleural fluid sugar (mean (SD), g/dl) 36 (40) 37 (47)
Pleural fluid culture positivity (n (%)) 38 (50) 16 (39)
Hemoglobin (mean (SD), g/dl) 10.4 (2.3) 10.4 (2.3)
TLC per mm3 (mean (SD)) 15,516 (7415) 14,968 (11,536)
Serum albumin (mean (SD); g/dl) 2.9 (0.5) 2.9 (0.6)
PaO2 (mean (SD), mm Hg) 61 (11) 61 (12)
Po 0.05.
P. Malhotra et al.426no statistically significant difference in ADA level in
tuberculous vs. other causes of empyema.
No cause was identifiable in 12 cases of empyema even
after extensive investigation, including CT of the chest and
these cases were therefore labeled idiopathic or primary
empyema.
The aetiologic spectrum of the 49 cases with BPF was as
follows: tuberculosis in 32 (65.3%), community acquired
pneumonia/lung abscess in 11 (22.5%), superinfection of
pre-existing spontaneous pneumothorax in 5 (10.2%) and as
a complication of amebic liver abscess in one (2%) patient.Modalities of treatment
All patients received broad-spectrum intravenous antibiotics
for periods ranging from 7–28 days followed by appropriate
oral antibiotics for 14–30 days. Anti-tubercular therapy was
administered to the 41 patients with tuberculosis for periods
ranging from 6–9 months depending on clinical, radiological
and microbiologic improvement. Intercostal tube drainage(ICTD) was used for pleural drainage in 95 patients, while 22
patients underwent primary pigtail catheter drainage.
Sixteen patients required both procedures. Median time of
insertion of ICTD following symptom onset was 10 days and
median duration of ICTD was 20 days. Intra-pleural
streptokinase (STK) was used in 20 patients (18 with non-
tuberculous and 2 with tuberculous empyema). Successful
drainage defined as subjective and objective clinical
improvement, adequate pleural drainage and radiological
resolution was seen in 17 (85%) patients. There were no
complications. Decortication by surgical thoracotomy was
performed in 6 (5.2%) patients (three each with tuberculous
and non-tuberculous empyema) who had severe restriction
on spirometry. Median time to surgery following symptom
onset was 55 days. The median duration of post-operative
pleural drainage by ICTD was 22.5 days.
Significantly more patients with non-tuberculous empye-
ma received intrapleural STK. Among the outcome measures
studied, time to resolution of fever, duration of pleural
drainage and pleural thickening 42 cm were significantly
greater in the tuberculous empyema group. All patients with
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Table 2 Bacteria isolated in pleural fluid of patients
with non-tuberculous empyema.
Bacteria n (%)
Primary infection 45 (38.4)
Aerobic bacteria 41 (35)
Gram positive organisms 17 (14.5)
S. aureus 9 (7.7)
Viridans streptococci 5 (4.3)
S. pneumoniae 1 (0.9)
S. pyogenes 1 (0.9)
Enterococcus fecalis 1 (0.9)
Gram negative organisms 24 (20.5)
P. aeruginosa 7 (6)
K. pneumoniae 7 (6)
E. coli 6 (5.1)
E. aerogenes 3 (2.6)
P. mirabilis 1 (0.9)
Anaerobic bacteria 4 (3.4)
Peptostreptococci 3 (2.5)
Bacteroides sp 1 (0.9)
Superinfection 27 (23.1)
Gram positive cocci (MRSA) 1 (0.9)
Gram negative bacilli 26 (22.2)
A. anitratus 15 (12.8)
P. aeruginosa 7 (6)
Alcaligenes fecalis 2 (1.8)
P. mirabilis 1 (0.9)
A. lwoffi 1 (0.9)
Table 3 Spectrum of aetiologic conditions responsible
for empyema.
Aetiologic condition n (%)
Bronchopulmonary infection 87 (74.3)
Tuberculosis 41 (35)
Community acquired pneumonia 32 (27.4)
Aspiration/ lung abscess 12 (10.3)
Ruptured hydatid cysts 1 (0.9)
Pulmonary infarction 1 (0.9)
Iatrogenic 8 (6.8)
Post ICTD for pneumothorax/malignant
pleural effusion
7 (6)
Post-pleural biopsy 1 (0.9)
Infra-diaphragmatic sepsis 6 (5.1)
Amoebic liver abscess 5 (4.4)




Ludwig’s angina 1 (0.9)
Tuberculous vs. non-tuberculous empyema thoracis 427positive acid fast bacilli on pleural fluid became negative
after a mean of 27.5 days (range 7–51). Eight patients with
non-tuberculous empyema and four with tuberculous em-pyema succumbed. These latter four patients succumbed
within 3 weeks of the start of anti-tubercular therapy.
Causes of death in the former were septic shock in five,
disseminated malignancy in two and respiratory failure in
one, while all patients with tuberculous empyema died due
to severe respiratory failure. Necropsy was performed in
three patients with tuberculous empyema (two probable
and one definite case) and revealed features of active TB in
all (extensive caseating AFB positive epitheloid cell granu-
lomas in the pulmonary parenchyma and pleura).Discussion
The fact that empyema remains a common clinical problem
in India is highlighted by the large number of cases (117 over
a 2-year period at a single center) included in this series in
comparison to other studies both from India as well as the
West some of which were multi-center studies carried out
over much longer periods of time.1–7,9–12
Pulmonary infections including community-acquired
pneumonia, aspiration pneumonia as well as suppurative
lung diseases like bronchiectasis and lung abscess are the
commonest causes of thoracic empyema in the West.
Surgical trauma ranks as the second most frequent cause.1–8
In contrast most studies from India reveal that tuberculosis
accounts for a large number of empyemas with figures
ranging from 29% to 85.1% of all cases.10–12,13–15 In fact till
the mid-1980s tuberculosis was the commonest aetiology of
thoracic empyema in India. However more recent studies
including ours indicate that tuberculosis now ranks second
to bacterial pneumonia as a cause for empyema.10,12 This
may be due to the wider availability of anti-tubercular drugs
and an increasingly effective tuberculosis control pro-
gramme.
Tuberculous empyema thoracis usually occurs when case-
ous material from a superficial parenchymal cavity ruptures
into the pleural space. It may also develop secondary to
paratracheal lymph node involvement, by direct extension
of a paravertebral cold abscess, progression of a primary
tuberculous pleural effusion itself or from haematogenous
spread of infection.15,16 Though it is often expected that
tuberculous empyema should be teeming with mycobacter-
ia, this may not be the case in clinical practice as
M. tuberculosis is an aerobic bacterium and the acidic and
anaerobic pleural environment of patients with empyema
may hinder its growth thus resulting in positive smears but
negative cultures.17 This was the case in 20 of our patients
with tuberculous empyema, only five of whom were culture
positive. However technical factors may have also con-
tributed to this low culture positivity rate. We used the
standard NALC–NaOH (N-acetyl L-cystine sodium hydroxide)
method of concentration and decontamination of speci-
mens.18 The specimens (5ml) were mixed with an equal
quantity of NALC–NaOH and left for 20min of exposure. We
then added 20ml of PBS pH 6.8 to neutralise the alkalinity,
and centrifuged the mixture. The deposit was used to
inoculate two vials of LJ medium incubated for up to 4
weeks aerobically at 37 1C. This method is considered by
some experts to be too harsh and can lead to loss of viability
of mycobacteria to an extent of up to 80%. Many workers
recommend assessing the load of contamination by an initial
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degree of contamination to shorter lengths of time
(5–10min) to the NALC–NaOH to preserve mycobacterial
viability. However, ours is a referral centre in a country with
a very high specimen load of samples for M.TB and, since
this was a prospective, ‘‘real-life’’ study it was difficult to
give customised attention to each specimen. In addition,
BACTEC was not available during the study period and
samples were inoculated onto conventional culture media
(LJ medium) which have a lower sensitivity compared to the
former.19 In the remaining 21 patients who had pleural
empyema with co-existent pulmonary tuberculosis (diag-
nosed on the basis of positive sputum smears for AFB, CT
evidence of active TB and clinical as well as microbiological
response to anti-tubercular therapy), three smears of the
pleural fluid were negative for AFB. To make a definitive
diagnosis of tuberculous empyema in these patients one
would have had to demonstrate simultaneous positivity for
AFB/M.TB in both sputum and pleural fluid samples, and
therefore these cases were considered to have probable
tuberculous empyema (Table 4).
Measurement of pleural fluid adenosine deaminase (ADA)
is diagnostically useful in differentiating tuberculous effu-
sions from other causes of exudative effusions. Unfortu-
nately it is of less value in empyema as levels tend to be high
in empyema of any aetiology.20 This was the case in our
study as well, with no statistically significant difference in
values between tuberculous and non-tuberculous aetiologies
of empyema.
Tuberculous empyema remains a major problem in
developing countries despite the availability of potent
anti-tubercular drugs and improved surgical techniques.
The invariable presence of concomitant fibrocavitary par-
enchymal disease, high bacillary load, frequent develop-
ment of bronchopleural fistulae and poor general condition
of patients combine to ensure significant morbidity and
mortality for this disease.16 In the present study clinical
characteristics and outcomes of patients with tuberculous
empyema were compared with non-tuberculous causes of
empyema. In concordance with other authors we found that




Intrapleural streptokinase (n (%)) 18
Pigtail catheter drainage (n (%)) 16
Duration of hospitalization (median, days) 16
Duration of pleural drainage (median, days) 14
Resolution of fever (n ¼ 86)(median, days)  5
Surgery (n (%)) 3
Pleural thickening
o2 cm (n (%)) 28
42 cm(n (%)) 48
Mortality (n (%)) 8
Po0.05.patients.15,21,22 This is primarily due to the high incidence
of pulmonary tuberculosis in this age group. Not surprisingly,
duration of symptoms and frequency of malnutrition were
significantly greater in patients with tuberculous empyema.
Tuberculous empyema is typically chronic as compared to
pyogenic causes, which often have a dramatic and sudden
onset with severe systemic symptoms.16 Most patients with
PTB are chronically ill with fever, cough, expectoration and
dyspnoea due to underlying fibrocavitary disease and the
supervention of pleural involvement often is clinically
silent. In some patients the inflammatory process may go
on for months or years with a paucity of clinical symptoms.
This prolonged asymptomatic course may be explained by
the formation of a thick pleural rind that virtually isolates
the tubercle bacilli to the pleural space.23 In addition, the
frequent co-existence of malnutrition also may decrease the
severity of the systemic inflammatory response syndrome,
further masking the onset of this complication.
Intrapleural streptokinase could only be administered in
two patients with tuberculous empyema in our study while
18 patients with non-tuberculous empyema received the
drug. Almost 80% of the patients with tuberculous empyema
had bronchopleural fistulae and in such patients the
administration of STK is contraindicated due to the risk of
spill over of the agent into the lung parenchyma. In
addition, median duration of symptoms in patients with
tuberculous empyema was 37.5 days, meaning that most
patients were already in the fibrino-purulent or organising
stage of empyema in which the effectiveness of STK is
expected to be markedly reduced.
Most outcome variables studied including duration of
hospitalisation, duration of pleural drainage and time to
fever resolution were significantly longer in the tuberculosis
group. There are several explanations for this. First
tuberculous empyema is usually chronic and most patients
have significant pleural fibrosis which limits the entry of
drugs into the pleural space. In addition, the frequent
presence of septations due to the chronic nature of the
empyema makes pleural drainage with a single tube
difficult.24 Second, the concomitant presence of BPF
























Age, mean (SD) 39.4 (15.9) 43.9 (16.5) 1.01 (1.003–1.02) 0.99 (0.97–1.01)
Female gender (n, %) 25 (78.1) 7 (21.9) 3.57 (1.54–8.25) 4.15 (0.97–17.68)
Duration of symptoms (days, mean (SD)) 32.94 (29.3) 23.06 (22.3) 1.02 (1.007–1.03) 0.98 (0.95–1.01)
Diabetes mellitus (n, %) 13 (65) 7 (35) 1.86 (0.74–4.6) —
Other comorbid illness 39 (70.9) 16 (22.1) 3.14 (1.34–7.36) 1.56 (0.35–6.95)
Current smokers (n, %) 17 (53.1) 15 (46.9) 1.13 (0.56–2.27) —
Alcoholism (n, %) 11 (78.6) 3 (21.4) 3.67 (1.02–13.14) 2.72 (0.38–19.57)
BMIo18.5 kg/m2 (n, %) 36 (80) 9 (20) 4.00 (1.93–8.30) 2.13 (0.61–7.36)
Large effusion (n, %) 16 (72.7) 6 (27.3) 2.67 (1.04–6.81) 1.02 (0.26–3.89)
Bronchopleural fistula (n, %) 45 (91.8) 4 (8.2) 11.25 (4.05–31.28) 6.65 (1.55–28.47)
Tuberculous aetiology (n, %) 35 (85.3) 6 (14.7) 5.83 (2.45–13.86) 5.73 (0.91–36.27)
Culture positivity (n, %) 39 (72.2) 15 (27.8) 2.60 (1.43–4.71) 1.41 (0.51–3.91)
Streptokinase administration (n, %) 10 (50) 10 (50) 2.23 (1.45–3.43) 0.76 (0.23–2.52)
Tuberculous vs. non-tuberculous empyema thoracis 429with both mycobacteria and other respiratory pathogens.
This is illustrated by the finding of superimposed bacterial
infection in 24 out of 41 (58%) cases of tuberculous
empyema in the present series which was statistically
significantly more than in non-tuberculous empyema.
Finally, as seen in other studies patients with this affliction
were more likely to be malnourished and thus have
compromised host defenses.
The mortality in patients with tuberculous empyema
reported in the present study 4/41 (9.8%) is comparable to
that seen in other studies and is similar to that of non-
tuberculous etiologies of empyema.12,15,21,24 Patients with
tuberculous empyema are frequently debilitated and have
concomitant pulmonary parenchymal disease making them
poor surgical candidates. In addition, they are more prone
to develop post-operative complications like secondary
bacterial infections, respiratory failure and bronchial stump
dehiscence. Surgery is also technically complex because of
the obscuration of traditional anatomic landmarks by the
fibrocalcific pleura. The low mortality seen in our study with
conservative management in the form of prolonged tube-
thoracostomy or pigtail drainage suggests that high-risk
patients may be successfully managed without resorting to
more invasive procedures like thoracotomy.
Poor outcomes, defined as duration of tube thoracostomy
for more than 14 days and/ or death were seen in 77 (65.8%)
patients. Risk factors for poor outcomes were evaluated
initially using univariate analysis to derive crude odds ratio,
and if found significant (Po0.1) these variables were then
entered in a multivariate logistic (Table 5). The presence of
a bronchopleural fistula was significantly associated with
poor outcomes on multivariate logistic regression analysis
while two other factors that approached significance were
female gender and tuberculous aetiology. Female patients in
India and other developing countries often present late to
hospital due to social circumstances and this may be an
explanation for relatively poorer outcomes. The reasons for
expecting worse outcomes in tuberculous empyema have
already been dealt with above, and it is possible that if
larger numbers were present in our study, some of the riskfactors for poor outcomes may have assumed statistical
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